AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 2725163
Drug: Ototopical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ototopical treatment (nonallergenic disinfectants)
Trial: 2725163
Drug: Azactam (systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azactam (systemic treatment)
Trial: 2725163
Drug: Sulfamethoxazole plus
RxNorm normalized name: Sulfamethoxazole
DrugBank: Sulfamethoxazole (DB01015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulfamethoxazole plus trimethoprim (systemic treatment)
Trial: 2725163
Drug: Ciprofloxacin (systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (systemic treatment)
Trial: 2725163
Drug: Ciprofloxacin plus
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin plus metronidazole (systemic treatment)
Trial: 786170
Drug: 0.3% tretinoin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3% tretinoin followed by a potent corticosteroid ointment
Trial: 786170
Drug: Corticosteroid ointment
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid ointment alone
Trial: 27702846
Drug: Fluoxetine (10-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (10-40 mg daily)
Trial: 22669936
Drug: Family therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family therapy in the context of palliative care
Trial: 22041483
Drug: Timolol eye
RxNorm normalized name: timolol
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Timolol eye drops administered topically twice per day from the second week through the end of the first month.
Trial: 22041483
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no timolol treatment).
Trial: 18845976
Drug: Nonvibration treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonvibration treatment with passive stretching for five 1-min bouts
Trial: 10651782
Drug: Azelastine 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelastine 4 mg (oral) once daily for 7 days
Trial: 12013487
Drug: Trandolapril 2
RxNorm normalized name: trandolapril 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trandolapril 2 mg once daily in the morning for 4 weeks
Trial: 1538580
Drug: Coenzyme Q10
RxNorm normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Coenzyme Q10 (30 mg/day)
Trial: 1980464
Drug: Lormetazepam 1
RxNorm normalized name: lormetazepam 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lormetazepam 1 mg
Trial: 22804943
Drug: Traditional multimodality
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional multimodality therapy (gastrolavage, catharsis, methylthioninium chloride, vitamin C, symptomatic treatment)
Trial: 22804943
Drug: Traditional multimodality
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional multimodality therapy plus scopolamine
Trial: 19789153
Drug: Colesevelam hydrochloride,
RxNorm normalized name: Colesevelam Hydrochloride, 625 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colesevelam hydrochloride, 3.75 g daily
Trial: 19789153
Drug: Rosiglitazone maleate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosiglitazone maleate, 4 mg daily
Trial: 19789153
Drug: Sitagliptin phosphate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin phosphate, 100 mg daily
Trial: 17983363
Drug: 45 degrees
RxNorm normalized name: NEEDLE 20G 1IN BENT 90 DEGREES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 45 degrees raised head of bed (treatment group)
Trial: 12946091
Drug: evidence-based consumer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: evidence-based consumer guide to treatments for depression
Trial: 17305661
Drug: Dexamethasone 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 0.6 mg/kg
Trial: 9197291
Drug: Low-flow sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-flow sevoflurane anesthesia (1 l/min)
Trial: 9197291
Drug: High-flow sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-flow sevoflurane anesthesia (6-10 l/min)
Trial: 9197291
Drug: Low-flow isoflurane
RxNorm normalized name: Isoflurane
DrugBank: Isoflurane (DB00753)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-flow isoflurane anesthesia (1 l/min)
Trial: 7951525
Drug: MCI‐028 (synthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCI‐028 (synthetic human corticotropin-releasing hormone) at doses of 33, 100, and 200 micrograms
Trial: 7951525
Drug: MCI‐028 (synthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCI‐028 (synthetic human corticotropin-releasing hormone)
Trial: 3082506
Drug: Monochemotherapy (thiotepa,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monochemotherapy (thiotepa, six courses, 200 mg each course)
Trial: 24850114
Drug: Local anesthetic
RxNorm normalized name: Local anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthetic with steroids (Group II)
Trial: 22414822
Drug: Buccal infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccal infiltration with 4% articaine with epinephrine
Trial: 22414822
Drug: Intraosseous injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraosseous injection with 2% lidocaine with epinephrine
Trial: 22414822
Drug: Intraligamentary injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraligamentary injection (PDL) with 2% lidocaine with epinephrine
Trial: 18377382
Drug: Oral triptans
RxNorm normalized name: TripTone Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral triptans
Trial: 18377382
Drug: Effervescent aspirin
RxNorm normalized name: aspirin Effervescent Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Effervescent aspirin
Trial: 15946914
Drug: Microemulsion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Microemulsion of cyclosporine, mycophenolatesodium, steroids and basiliximab
Trial: 15946914
Drug: Increased cyclosporine
RxNorm normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased cyclosporine (CsA) dose
Trial: 15946914
Drug: Decreased CsA
RxNorm normalized name: CsA
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decreased CsA dose after 14 days
Trial: 6810015
Drug: Long-acting insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting insulin preparation given once daily at variable doses
Trial: 25913664
Drug: BMS-582949 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS-582949 (100 mg once daily)
Trial: 21295198
Drug: Warfarin management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin management communication protocol using SBAR approach
Trial: 15261316
Drug: MgSO4 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MgSO4 (50 mg kg(‐1) in 100 mL saline, followed by 50 mL hr(‐1) infusion of MgSO4 (15 mg kg(‐1) hr(‐1))
Trial: 11389256
Drug: Nitric oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitric oxide treatment for PPHN
Trial: 11389256
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no nitric oxide treatment)
Trial: 26376350
Drug: Tofacitinib (0.5,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib (0.5, 3, 10, or 15 mg twice daily)
Trial: 23221981
Drug: ALVAC-HIV vCP1521
RxNorm normalized name: HIV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ALVAC-HIV vCP1521 vaccine
Trial: 22842667
Drug: PTH (1‐34)
RxNorm normalized name: PTH
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PTH (1‐34) 20 μg
Trial: 22842667
Drug: PTH (1‐84)
RxNorm normalized name: PTH
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PTH (1‐84) 100 μg
Trial: 11986563
Drug: static with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: static with MC plus blur correction plus AC (combined corrections [CC])
Trial: 11986563
Drug: gated with
RxNorm normalized name: GLUCAGON ANALOG CONJUGATED WITH HUMAN IMMUNOGLOBULIN G4 FRAGMENT
DrugBank: Efocipegtrutide (DB18194)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gated with CC
Trial: 9653864
Drug: High-dose danazol
RxNorm normalized name: Danazol
DrugBank: Danazol (DB01406)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose danazol (600 mg daily)
Trial: 9653864
Drug: Low-dose danazol
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose danazol (200 mg daily) plus placebo tablets
Trial: 7664720
Drug: Biologically fermented
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biologically fermented milk product (200 ml/day)
Trial: 7664720
Drug: Placebo product
RxNorm normalized name: placebo Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo product (200 ml/day)
Trial: 2474017
Drug: L-5-hydroxytryptophan (L5HTP;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-5-hydroxytryptophan (L5HTP; 100 mg qid) with carbidopa (C; 50 mg qid)
Trial: 26580831
Drug: Topical glycerol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical glycerol trinitrate (2g once a day for 3 days before laser sessions)
Trial: 23229188
Drug: Methotrexate (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (7.5 mg/week)
Trial: 23229188
Drug: Cyclosporine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine (2.5 mg/kg/day)
Trial: 16461867
Drug: Primary care,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Primary care, office‐based, computer‐assisted diet and PA assessment and stage‐based goal setting followed by brief health care provider counseling and 12 months of monthly mail and telephone counseling
Trial: 9287262
Drug: 60 mmol/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mmol/day potassium supplement for four weeks
Trial: 9287262
Drug: 48 mmol/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 48 mmol/day potassium supplement for four months
Trial: 8346578
Drug: Corticosteroid (CS)
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid (CS) therapy - intravenous methylprednisolone 2 mg/kg bodyweight daily for ten days
Trial: 8346578
Drug: Cotrimoxazole (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cotrimoxazole (standard treatment)
Trial: 3555175
Drug: Nicardipine 20
RxNorm normalized name: nicardipine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicardipine 20 mg three times a day for two weeks
Trial: 22927230
Drug: Sufentanil 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil 0.4 ng/mL (group SL)
Trial: 22927230
Drug: Sufentanil 0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil 0.8 ng/mL (group SH)
Trial: 21353695
Drug: Denosumab (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Denosumab (120 mg subcutaneous every 4 weeks)
Trial: 21353695
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (4 mg intravenous every 4 weeks)
Trial: 19608171
Drug: Supraphysiologic (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supraphysiologic (0.2 mg/d transdermal E(2) and vaginal micronized E(2))
Trial: 19608171
Drug: Physiologic (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiologic (0.2 mg/d transdermal E(2))
Trial: 19608171
Drug: Subphysiologic (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subphysiologic (no exogenous E(2) treatment)
Trial: 15321697
Drug: Quinidine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinidine + Verapamil (high dose) 480/240 mg/d
Trial: 15321697
Drug: Quinidine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinidine + Verapamil (low dose) 320/160 mg/d
Trial: 15321697
Drug: Sotalol 320
RxNorm normalized name: sotalol 320 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotalol 320 mg/d
Trial: 15321697
Drug: Quinidine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinidine + Verapamil (high dose)
Trial: 15321697
Drug: Quinidine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinidine + Verapamil (low dose)
Trial: 15321697
Drug: All active
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All active treatments (Quinidine + Verapamil high dose, low dose, Sotalol)
Trial: 9671326
Drug: Epoetin alfa
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epoetin alfa 150 IU/kg three times weekly
Trial: 3288951
Drug: Oxybutynin 10
RxNorm normalized name: oxyBUTYnin 10% transdermal gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxybutynin 10 mg at suppertime for 28 days
Trial: 20411996
Drug: MPA 10
RxNorm normalized name: Fycompa 10mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPA 10 mg/day
Trial: 20411996
Drug: CEE 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE 0.6 mg/day
Trial: 16582549
Drug: QUANTEC treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QUANTEC treatment for 3 months
Trial: 16582549
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no treatment during first phase)
Trial: 11061470
Drug: Budesonide 64
RxNorm normalized name: budesonide 64 MCG/ACTUAT Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 64 microg aqueous nasal spray
Trial: 11061470
Drug: Budesonide 256
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide 256 microg aqueous nasal spray
Trial: 8942009
Drug: salmeterol 50
RxNorm normalized name: FLUTICAS 100/SALMETEROL 50 INHL DISK 14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: salmeterol 50 micrograms twice daily
Trial: 8655889
Drug: salbutamol 200
RxNorm normalized name: Salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: salbutamol 200 micrograms twice daily
Trial: 1417196
Drug: New polyvalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New polyvalent melanoma cell vaccine (MCV)
Trial: 1417196
Drug: Historical database
RxNorm normalized name: typhus, historical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Historical database of previous immunotherapy and other treatments
Trial: 2864709
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg bromazepam per day
Trial: 2864709
Drug: 1.5 mg
RxNorm normalized name: boron 1.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg fluspirilene per week
Trial: 30266894
Drug: low‐flu/val (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: low‐flu/val (10 mg/20 mg)
Trial: 20855047
Drug: Both Sertraline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both Sertraline and CBT (COMB)
Trial: 20855047
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) without family history of OCD
Trial: 14752209
Drug: Sex hormone
RxNorm normalized name: Sex hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sex hormone replacement therapy
Trial: 8135108
Drug: Seaprose S
RxNorm normalized name: S-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seaprose S (30 mg tablets, 3 tab/day)
Trial: 8135108
Drug: Nimesulide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimesulide (100 mg, 2 tab/day)
Trial: 30932776
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acid supplementation (330 mg) and vitamin D3 (0.005 mg or 200 IU) per day
Trial: 20197486
Drug: laropiprant 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: laropiprant 40 mg for 10 days + single-dose digoxin 0.5 mg
Trial: 20197486
Drug: single-dose digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single-dose digoxin 0.5 mg
Trial: 12814902
Drug: Ethanol (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (0.4 g/kg, 22‐28 g) twice daily for 8 days
Trial: 8936546
Drug: Caudal bupivicaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal bupivicaine (0.25%) 2 mg.kg-1 before surgical incision, followed by caudal normal saline infused at the same volume after surgical incision.
Trial: 6387197
Drug: Timolol maleate,
RxNorm normalized name: Timolol Maleate, Ophthalmic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol maleate, 20 to 30 mg/day
Trial: 27817811
Drug: GFF MDI
RxNorm normalized name: MDI-P
DrugBank: 3,4-Methylenedioxy-N-isopropylamphetamine (DB06112)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GFF MDI 18/9.6 μg
Trial: 27817811
Drug: GP MDI
RxNorm normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GP MDI 18 μg
Trial: 27817811
Drug: FF MDI
RxNorm normalized name: FF-10101-01
DrugBank: FF-10101-01 (DB16050)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FF MDI 9.6 μg
Trial: 26882607
Drug: External use
RxNorm normalized name: For External Use Only Label
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External use of Shengji Ointment (SO), exchange once every 24 h for 21 days
Trial: 22652506
Drug: 20 mg/day
RxNorm normalized name: futibatinib 20 mg/day (4 mg x 5) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg/day lutein (L), 2 mg/day zeaxanthin (Z)
Trial: 22652506
Drug: 10 mg/day
RxNorm normalized name: Adlarity 10 MG/Day Weekly Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/day meso‐zeaxanthin (MZ), 10 mg/day lutein (L), 2 mg/day zeaxanthin (Z)
Trial: 22652506
Drug: 17 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17 mg/day meso‐zeaxanthin (MZ), 3 mg/day lutein (L), 2 mg/day zeaxanthin (Z)
Trial: 12232543
Drug: tianeptine (37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tianeptine (37.5 mg)
Trial: 12232543
Drug: sertraline (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sertraline (50 mg)
Trial: 15662091
Drug: Simvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (20 mg/d)
Trial: 1979463
Drug: Routine maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine maintenance therapy
Trial: 6311785
Drug: Ceftizoxime (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftizoxime (1 g) administered by iv rapid injection
Trial: 6311785
Drug: Ceftizoxime (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftizoxime (1 g) administered by im injection
Trial: 6311785
Drug: Probenecid (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probenecid (1 g) administered one hour before ceftizoxime
Trial: 31249252
Drug: dexmedetomidine 10
RxNorm normalized name: dexmedeTOMIDine 1000 MG in 250 mL Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dexmedetomidine 10 μg/kg
Trial: 31249252
Drug: dexmedetomidine 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dexmedetomidine 5 μg/kg
Trial: 26945402
Drug: hMG (150-225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hMG (150-225 IU) and MPA (10 mg/d) administered simultaneously starting on cycle day 3
Trial: 21094811
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa (DA) therapy for 3 months
Trial: 21094811
Drug: Darbepoetin alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Darbepoetin alfa (DA) therapy
Trial: 16985503
Drug: Alcohol (0,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol (0, 0.02-0.04 mg%, or 0.06-0.08 mg%)
Trial: 1344238
Drug: 2% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine 1.5 mg/kg
Trial: 1344238
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (N/S) 0.1 ml/kg (control group)
Trial: 6141161
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg clorazepate
Trial: 6141161
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg clorazepate
Trial: 22957889
Drug: Specific oral
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific oral tolerance induction (SOTI) with raw hen's egg emulsion for 6 months
Trial: 12928692
Drug: Acetazolamide 250
RxNorm normalized name: acetazolamide 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide 250 mg twice daily (b.i.d.)
Trial: 8848989
Drug: Indapamide 2.5
RxNorm normalized name: indapamide 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indapamide 2.5 mg/day
Trial: 8853772
Drug: Bile acids
RxNorm normalized name: Conjugated bile acids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bile acids (ursodeoxycholic acid 500 mg and chenodeoxycholic acid 500 mg per day)